ARGENX Platform trial
About this clinical research study:
Adapt Forward is a platform of studies designed for people living with MG. It consists of several studies that are meant to evaluate how different combinations and regimens of MG drugs may work (also known as efficacy) and how safe they are for the use in adults living with MG. Different investigational study drugs or combinations of different study drugs are evaluated in the platform studies. In some studies, the study drug is compared to a placebo and in others it’s compared to other MG study drugs. Different regimens are evaluated in the different studies. It is important to understand that these study drugs/combinations have not been approved by health authorities for the use(s) being studied
Eligibility (Age, Condition):
At least 18 years old.
Not pregnant, or actively trying to get pregnant.
Diagnosed with MG.
Additional eligibility criteria apply per study.
What to expect:
A study consists of below phases: Master protocol screening: A screening process to check eligibility will be initiated. This includes laboratory tests, a physical examination, review of medical history and MG medication history, and completing questionnaires. If qualified to participate in the Platform, the results will be reviewed to determine which studies running under this platform may be best and a more detailed check will be done to find out further eligibility.
Treatment phase: If eligible to join a study, the participant will be assigned to receive the investigational study drug(s) in accordance to the study regimen of the assigned study. Follow up phase: After the treatment phase, the study team will continue to monitor for safety. Additional eligibility criteria per study apply.